ERcast: Clinical Perspectives Podcast Preview

Subscription Required

Eli's Story: The Fentanyl Crisis

Beth Weinstock, MD, Solomon Behar, MD, and Neda Frayha, MD

Sign in or Subscribe to listen.
5 starson Spotify
Sign in or Subscribe to view.Sign in or Subscribe to view.

The summary below is from an episode of ERcast: Clinical Perspectives

Illicit fentanyl contamination now drives much of the U.S. overdose crisis, often through counterfeit pills, stimulants, and other non-opioid drugs. A lethal dose can be just 2 mg, and bedside harm reduction starts with clear patient education, naloxone access, and fentanyl test strips.

Fentanyl Poisoning and Harm Reduction

  • Counterfeit pill risk: Fentanyl now appears in counterfeit benzodiazepines and opioid tablets, as well as cocaine and methamphetamine, so many poisoned patients never intended to take an opioid.
  • Potency and lethality: Fentanyl is about 100 times more potent than morphine, and lethal contamination became common as the illicit market shifted after 2013.
  • Overdose death burden: Synthetic opioids were involved in 67% of more than 107,000 U.S. overdose deaths in a single year, underscoring why this is now core clinical counseling, not a niche topic.
  • Test strip performance: Fentanyl test strips have roughly 92% to 96% sensitivity and give patients actionable information before use. We walk through the practical counseling angle in the episode.
  • Incidental exposure myth: Brief dermal fentanyl exposure is unlikely to cause toxicity; removing visible residue and focusing on airway, breathing, and CPR matters more than panic.
  • Stage-based clinician response: Harm reduction starts with meeting patients where they are in addiction readiness, then using every encounter to educate, equip, and keep them alive until treatment is possible.

Eli's Story and Community Response

  • Unintentional fentanyl death: Eli's death illustrates a central reality of this crisis: many young people ingest fentanyl unknowingly and do not intend self-harm or overdose.
  • Kratom plus fentanyl: The coroner identified kratom and fentanyl, a reminder that legal or familiar substances do not exclude dangerous adulteration from the broader drug supply.
  • Rainbow fentanyl targeting: Colorful pills and powders marketed as rainbow fentanyl are designed to appeal to younger users, adding a prevention challenge for families, schools, and clinicians.
  • Patient education script: A simple question like asking whether someone has heard of counterfeit pills can open the door to counseling; one cited estimate is that about 20% contain fentanyl.
  • BirdieLight resources: BirdieLight focuses fentanyl education on ages 14 to 25 while also supporting clinicians, educators, and families with curricula and test-strip access. We get into those community tools in the chapter.

Subscribe to ERcast: Clinical Perspectives to listen to the episode.

References:

  1. Gardner EA, et al. The Opioid Crisis: Prevalence and Markets of Opioids. Forensic Sci Rev. 2022 Jan;34(1):43-70. PMID: 35105535.
  2. Lutfy K. Opioid Crisis-An Emphasis on Fentanyl Analogs. Brain Sci. 2020 Jul 27;10(8):485. doi: 10.3390/brainsci10080485. PMID: 32726995.
  3. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350. PMID: 33965972.
  4. Park JN, et al. Polysubstance Overdose Deaths in the Fentanyl Era: A Latent Class Analysis. J Addict Med. 2022 Jan-Feb 01;16(1):49-55. PMID: 33675604.
  5. Althoff KN, et al. Opioid-related overdose mortality in the era of fentanyl: Monitoring a shifting epidemic by person, place, and time. Drug Alcohol Depend. 2020 Nov 1;216:108321. Epub 2020 Sep 25. PMID: 33007700.
  6. Fentanyl Awareness. United States Drug Enforcement Administration. Link. 
  7. Facts About Fentanyl. United States Drug Enforcement Administration. Link.
  8. Department of Justice/Drug Enforcement Administration Drug Fact Sheet: Fentanyl. Link. 

Faculty